Prescribe With Confidence
At Mantara, we use state-of-the-art DNA testing technology and the latest pharmacogenomic evidence to support your medical decision-making.
The Science Behind Our Test
Every Mantara PGx report is built on guidance from leading pharmacogenomic experts across the UK and Europe. Our approach follows the same protocol and recommendations used in the UPGx study published in The Lancet (2023), giving you clinically robust information to support prescribing more accurately within approved guidelines.
World-Class DNA Testing
Our partner laboratory in Germany is a specialist provider of advanced genetic testing. Highly experienced geneticists and laboratory scientists use validated, high‑precision analysers to deliver reliable DNA genotyping suitable for pharmacogenomic reporting. Our reporting software is fully validated, accredited by the College of American Pathologists, and was used throughout the European UPGx project—ensuring the results your patients share with you meet the highest standards.
High Quality Reporting
We work with bio.logis to provide clear, clinically actionable interpretation using CE‑ and UKCA‑marked medical device software developed for the UPGx study. Each report highlights whether a patient’s genotype should influence prescribing decisions, alongside all other clinical considerations.
Many SmPCs already include recommendations based on genetic information. A Mantara® PGx report brings this guidance directly into your workflow, supporting confident, evidence‑based prescribing.
The Basis of Our Recommendations
Our reports include only fully actionable recommendations from the Dutch Pharmacogenetics Working Group (DPWG) and findings from the PREPARE study, which included the University of Liverpool. This ensures you receive high‑quality, clinically relevant advice you can rely on.
Some commercial tests include “informational” recommendations that have not yet met DPWG criteria for actionability. Mantara does not include these until the evidence base is strong enough to support clinical use.
Recent Research: the UPGx Trial
The Ubiquitous Pharmacogenomics (UPGx) study is the largest pharmacogenomics trial ever conducted in Europe, including the UK, with around 7,000 patients taking part. Its goal was to evaluate whether pre‑emptive genotyping of a broad panel of pharmacogenomic markers could improve patient outcomes and be cost‑effective.
Published in The Lancet, the results showed that tailoring medication doses based on a patient’s genetic profile led to a 30% reduction in serious side effects. The study was led by leading European experts in pharmacogenetics, including the NHS Chair of Pharmacogenetics at the University of Liverpool, and has set a new benchmark for bringing pharmacogenomics into routine clinical care.
A key achievement of UPGx was the introduction of a “DNA medication pass,” demonstrating how personalised prescribing can significantly enhance patient safety and treatment effectiveness. The trial marks a major step forward for personalised medicine and is expected to influence future research and clinical implementation across Europe.
Mantara’s test follows the same laboratory standards and guidelines used in the UPGx study.
Book a Free 10-Minute Call to Find Out More
If you are a healthcare professional who would like to get involved with pharmacogenomics, either to provide the Mantara PGx DNA Test to your patients or to take part in research, please don’t hesitate to get in touch. Click on the button below to schedule a free 10-minute call.
Exclusive Partnership With World-Class Laboratory
Comprehensive Test Shows Results for 12 Genes
CE and UKCA Marked PGx DNA Test Kits
To learn more about pharmacogenomics, head over to our resource centre where you’ll find further research, the latest news coverage and educational material.